Soligenix Inc. (NASDAQ: SNGX) announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behçet's disease. This regulatory milestone is expected to lead to orphan drug designation by the European Commission, offering significant incentives for the development of the therapy.
Christopher J. Schaber, PhD, CEO and president of Soligenix, stated, "We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program." The designation provides benefits including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity following approval in the European Union.
Dusquetide is an innate defense regulator (IDR), a novel class of compounds designed to modulate the body's innate immune system rather than suppress it. This mechanism offers a potential therapeutic approach for inflammatory diseases without broadly suppressing immunity. Behçet's disease is a rare, chronic inflammatory condition affecting blood vessels, causing symptoms such as oral and genital ulcers, skin lesions, and eye inflammation. Current treatments often involve immunosuppressants, which carry significant side effects.
The positive EMA opinion validates the scientific rationale behind dusquetide and unlocks development incentives that can accelerate its path to patients. For individuals living with rare inflammatory diseases, such regulatory milestones can transform stalled research into meaningful therapeutic progress. Soligenix is advancing the SGX945 program (dusquetide) for Behçet's disease, addressing an area of unmet medical need.
Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need. The company's pipeline includes therapies for inflammatory diseases and biodefense indications. More information about Soligenix and the dusquetide program can be found in the company's newsroom at https://ibn.fm/SNGX.
